Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Income (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Net Income over the past 3 years, most recently at -$46.9 million for Q4 2025.

  • Quarterly results put Net Income at -$46.9 million for Q4 2025, down 106.26% from a year ago — trailing twelve months through Dec 2025 was -$122.2 million (up 10.98% YoY), and the annual figure for FY2025 was -$121.6 million, up 11.8%.
  • Net Income for Q4 2025 was -$46.9 million at Tonix Pharmaceuticals Holding, down from -$31.8 million in the prior quarter.
  • Over the last five years, Net Income for TNXP hit a ceiling of -$15.8 million in Q3 2024 and a floor of -$77.3 million in Q2 2024.
  • Median Net Income over the past 3 years was -$27.7 million (2023), compared with a mean of -$31.4 million.
  • Biggest five-year swings in Net Income: plummeted 166.59% in 2024 and later skyrocketed 64.62% in 2025.
  • Tonix Pharmaceuticals Holding's Net Income stood at -$27.3 million in 2023, then increased by 16.7% to -$22.8 million in 2024, then tumbled by 106.26% to -$46.9 million in 2025.
  • The last three reported values for Net Income were -$46.9 million (Q4 2025), -$31.8 million (Q3 2025), and -$27.4 million (Q2 2025) per Business Quant data.